NRX Pharmaceuticals is trying to become a commercial ketamine supplier before its clinic network can carry the equity on its own. The Food and Drug Administration finished a first-cycle review of the company's preservative-free ketamine abbreviated new drug application with no drug-related major deficiencies, leaving only a manufacturer attestation on the vial's luer-lock tip. Management has already submitted that attestation and has begun building launch inventory. The equity now prices a near-term generic launch against a still-unresolved going-concern warning and a share count that jumped through a mid-year underwritten offering. The debate is whether packaging clearance plus clinic cash flow can fund a launch, or whether the capital stack keeps resetting before product sales arrive.
Clinic revenue appeared for the first time this year after HOPE Therapeutics closed Florida behavioral-health acquisitions, yet the run-rate is still a rounding error against operating spend. First-half patient-service revenue reached $2.2 million. The same period produced an operating loss of $11.3 million as research and selling costs rose ahead of a hoped-for ketamine launch. Cash climbed to $26.7 million after a public offering of more than $22 million, which is the only reason the runway discussion improved. Warrant liabilities also swelled as the share price recovered, so the accounting loss widened even as cash improved. The clinic line proves the company can bill patients; it does not yet prove the company can fund itself.
The June quarter also added a Defense Advanced Research Projects Agency selection as prime contractor for a mid-stage study of NRX-101 with robotic transcranial magnetic stimulation, plus a GeNeuro antibody portfolio and a subsequent-event termination of the Kadima clinic purchase. Those items pull in opposite directions: one is a non-dilutive military research path, the other is a broken clinic roll-up. Does the agency clear the remaining vial attestation in time for a commercial start this year, or does the issuer remain a going-concern story whose HOPE clinics and warrant stack dominate the residual claim?